Risk Markers and Appropriate Implantable Defibrillator Therapy in XXXX .

@entity1164 @entity1 @entity1165 @entity943 @entity737 @entity955 @entity1121
BACKGROUND: Risk stratification of @entity1164 in @entity1121 ( @entity1121 ) is mainly based on evaluations from @entity1 at highly specialized centers. AIM: To evaluate risk markers for appropriate @entity737 ( @entity737 ) therapy in an unselected, nationwide cohort of @entity1121 . METHODS: @entity1 with an @entity737 due to @entity1121 were identified from the Swedish @entity737 Registry since its start in 1995, merged with @entity1 Register data, and medical records were retrieved. Risk markers for @entity943 leading to appropriate @entity737 therapy were analyzed using Cox proportional hazard ratio (HR). RESULTS: Of 321 @entity1 (70.1% males), at least one appropriate therapy occurred in 77 (24.0%) during a mean follow-up of 5.4 years (5.3% per year; primary prevention 4.5%, secondary prevention 7.0%). Cumulative incidences at 1, 3, and 5 years were 8.1%, 15.3%, and 21.3% respectively. Cardioversion effectively restored rhythm in 52% of the first episode and antitachycardia pacing was sufficient in the remaining. For the whole cohort, ejection fraction (EF)<50% (HR 2.63; p<0.001), was associated with appropriate @entity737 therapy. In primary prevention, @entity1 with established risk markers experienced appropriate therapy; @entity955 (HR 2.54; p = 0.010), EF<50% (HR 2.78; p = 0.004), and nonsustained @entity1165 (HR 1.80; p = 0.109), had the highest HR, and wall thickness >= 30mm, syncope, exercise blood pressure response, or family history of @entity1164 had weaker associations. CONCLUSION: @entity737 therapy successfully terminates @entity943 in @entity1121 . In addition to conventional risk markers, a history of @entity955 or EF<50% may be considered in risk stratification. This article is protected by copyright. All rights reserved.
